Keywords:
Performed at one institution, Observational, Prospective, Cancer, Diagnostic procedure, MR, Cardiovascular system, Cardiac
Authors:
N. A. Atia1, L. Lehmann2, H. Goldschmidt2, F. André2, J. Salatzki2, M. G. friedrich3, H. Katus2, J. Riffel2; 1Tanta/EG, 2Heidelberg/DE, 3Montreal/CA
DOI:
10.26044/ecr2020/C-03068
Purpose
Carfilzomib is a novel, irreversible inhibitor of the proteasome’s chymotrypsin-like activity (see Figure 1). It is currently broadly used in relapsed or refractory multiple myeloma patients (1,2). Early, preclinical and clinical data point towards a cardiotoxic side effect due to the fast and highly efficient inhibition of the proteasome in cardiomyocytes (2). Although this drug is known to be cardiotoxic, so far there are only limited data about assessment of myocardial damage using cardiac MRI (CMR) and early identification of patients at risk.
Therefore, this prospective, observational, single center study aimed at identification of patients at risk based on myocardial deformation (strain) analysis by using state of the art CMR. Our hypothesis is to detect subclinical cardiotoxic events and to define parameters which could predict late cardiac changes after 3 months follow up in patients with multiple myeloma receiving Carfilzomib.